Tysabri® Multiple Sclerosis Clinical Trial Hold Lifted By FDA; Biogen IDEC And ELAN To Resume Clinical Trial Dosing In MS

... Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that the Food and Drug Administration (FDA) informed the companies that they have removed the hold on clinical trial dosing of TYSABRI® (natalizumab) in multiple sclerosis (MS) in the U.S. The companies expect to begin an open label, multi-center safety extension study of TYSABRI monotherapy in the U... click link for more info. ...